20 September 2018 - - Canadian biotechnology company Aspect Biosystems has forged a new collaboration to develop human liver tissue with JSR Corp., a materials supplier in a variety of technology driven markets, the company said.

Through this collaboration, Aspect's proprietary Lab-on-a-Printer 3D bioprinting platform and JSR's advanced materials technology will be used to develop vascularised human liver lobules.

Joining forces with the innovative team at JSR offers a great opportunity to develop a predictive and human-relevant liver tissue platform," said Tamer Mohamed, president and CEO of Aspect Biosystems.

Aspect Biosystems is a privately held biotechnology company operating in 3D bioprinting and tissue engineering.

The company's proprietary Lab-on-a-Printer platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine.

In addition to its internal tissue development programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues.

These tissues are used for impactful applications in therapeutic discovery and regenerative medicine. 

JSR Corp. is a multinational company with research-oriented organisation that pursues close collaborations with leading innovators in a number of industries that are a key to the present and future welfare of human society: life sciences, synthetic rubbers, electronic materials, display and optical materials.

The company conducts its global life sciences business through its JSR Life Sciences Business Division. JSR Life Sciences provides specialized materials, products and services to the biotech industry both directly and through its subsidiaries Medical and Biological Laboratories Co. Ltd, KBI Biopharma, Inc., Selexis SA, and Crown Biosciences.